Viral Vector Manufacturing Market

Lonza (Switzerland), Merck (Germany) and Oxford BioMedica (UK) are top players in Viral Vector Manufacturing Market

The global viral vector manufacturing market is projected to reach USD 815.8 million by 2023 from USD 327.8 million in 2018, at a CAGR of 20.0% during the forecast period. This market is consolidated in nature with a few global players. In 2017, Lonza (Switzerland), Merck (Germany), and Oxford BioMedica (UK), were the top three players in the viral vector manufacturing market.

Lonza (Switzerland) was the leading player in the viral vector manufacturing market in 2017. The company adopts organic as well as inorganic growth strategies to maintain its dominant position in the market. It entered into agreements with leading gene therapy companies to manufacture their gene therapy products for clinical and commercial use. The company expanded its manufacturing capabilities in the US in 2018 and acquired a leading cell and gene therapy manufacturer in the Netherlands in 2017 to enhance its market presence. Lonza also focuses on seeking growth opportunities in the emerging markets of APAC.

Merck (Germany) held the second position in the viral vector manufacturing market in 2017 and has a strong presence in the leading markets of the US and the UK. The company offers a continuum of viral vector manufacturing services and has collaborated with leading gene therapy companies. Merck’s strong foothold in the life sciences industry and significant revenue has allowed the company to expand its manufacturing capabilities in the US, further enhancing its market presence in the largest gene therapy market.

To know about the assumptions considered for the study download the pdf brochure

Oxford BioMedica (UK) was the third player in the viral vector manufacturing market in 2017. The company owns a broad and robust viral vector therapy pipeline allowing the company to collaborate with leading pharma and biopharma companies such as Novartis and Bioverativ (US). The company is a pioneer in developing lentiviral vector therapy using its proprietary LentiVector Platform. It also benefits from the out-licensing of this platform. Biomedica focuses on seeking opportunities in important markets such as South Korea, Switzerland, and Italy.

Some other important players in the global viral vector manufacturing market include CGT Catapult (UK), Cobra Biologics (UK), uniQure (Netherlands), FUJIFILM Diosynth Biotechnologies (US), Spark Therapeutics (US), REGENXBIO (US), FinVector (Finland), Novasep (France), Kaneka Eurogentec (Japan), and MassBiologics (US). These companies also have well-established viral vector manufacturing capabilities and are focused on expanding their market reach through collaborations with cell and gene therapy companies.

Related Reports:

Viral Vector Manufacturing Market by Type (Retrovirus, Gammaretrovirus, AAV), Disease (Cancer, Infectious Disease, Genetic Disorders), Application (Gene Therapy, Vaccinology), End User (Biotech companies, Research Institutes) - Global Forecast to 2023

Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com

Report Code
BT 6497
RI Published ON
8/2/2018
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Viral Vector Manufacturing Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
REQUEST A FREE WORKSHOP
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
ONLINE CHAT
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
© MarketsandMarkets Research Private Ltd. All rights reserved